

2025 HEALTHSUN Step Therapy Criteria

Dexilant - B

Products Affected

- dexlansoprazole capsule delayed release 30 mg oral*
- dexlansoprazole capsule delayed release 60 mg oral*

Details

Criteria	If the patient has tried ONE Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): omeprazole, pantoprazole, or lansoprazole. Step 2 Drug(s): Dexlansoprazole. New Starts
----------	--

MTX - B

Products Affected

- JYLAMVO SOLUTION 2 MG/ML ORAL
- XATMEP SOLUTION 2.5 MG/ML ORAL

Details

Criteria	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): oral methotrexate sodium. Step 2 Drug(s): Jylamvo (methotrexate), Xatmep (methotrexate).
-----------------	---

NP Bisphosphonates - H

Products Affected

- *risedronate sodium tablet 150 mg oral* *pack)*
- *risedronate sodium tablet 30 mg oral* • *risedronate sodium tablet 35 mg oral (4*
- *risedronate sodium tablet 35 mg oral* *pack)*
- *risedronate sodium tablet 35 mg oral (12* • *risedronate sodium tablet 5 mg oral*

Details

Criteria	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): Alendronate, ibandronate tablets. Step 2 Drug(s): Risedronate.
-----------------	--

Rytary

Products Affected

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): carbidopa, carbidopa/levodopa IR/ER. Step 2 Drug(s): Rytary (carbidopa/levodopa).
-----------------	---

ULORIC - B

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): allopurinol. Step 2 Drug(s): Febuxostat. Approve without trial of step 1 drug if Patient has contraindication to allopurinol use.
-----------------	---

Y0114_25_3012945_0000_I_C
1074450MUMENMUB

EFFECTIVE DATE 08/01/2025